Outlook Wealth Advisors LLC Purchases 517 Shares of Novo Nordisk A/S (NYSE:NVO)

Outlook Wealth Advisors LLC boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 17.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,400 shares of the company’s stock after acquiring an additional 517 shares during the period. Outlook Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $437,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. IFP Advisors Inc increased its stake in Novo Nordisk A/S by 61.6% during the 3rd quarter. IFP Advisors Inc now owns 4,244 shares of the company’s stock worth $386,000 after purchasing an additional 1,618 shares in the last quarter. Hartford Investment Management Co. increased its position in shares of Novo Nordisk A/S by 63.8% during the third quarter. Hartford Investment Management Co. now owns 3,924 shares of the company’s stock worth $357,000 after acquiring an additional 1,528 shares in the last quarter. Capital Investment Advisors LLC acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth $222,000. Park Place Capital Corp lifted its position in Novo Nordisk A/S by 118.7% in the 3rd quarter. Park Place Capital Corp now owns 584 shares of the company’s stock valued at $53,000 after acquiring an additional 317 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. boosted its stake in Novo Nordisk A/S by 69.1% in the 3rd quarter. Newbridge Financial Services Group Inc. now owns 487 shares of the company’s stock worth $44,000 after purchasing an additional 199 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 0.8 %

Shares of Novo Nordisk A/S stock traded up $1.06 on Friday, reaching $126.85. 3,312,457 shares of the company were exchanged, compared to its average volume of 3,307,405. The company has a market capitalization of $569.24 billion, a price-to-earnings ratio of 46.89, a PEG ratio of 2.10 and a beta of 0.41. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $138.28. The company has a 50-day moving average of $126.86 and a 200 day moving average of $111.98.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The business had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were issued a dividend of $0.664 per share. The ex-dividend date of this dividend was Friday, March 22nd. This represents a yield of 0.9%. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 49.17%.

Analysts Set New Price Targets

Several analysts have issued reports on NVO shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price on the stock. UBS Group began coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating for the company. Finally, Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.